



Technical Bulletin

Clostridioides (Clostridium) difficile PCR now available at Queen's Manamana and Queen's West Oahu laboratories

TO: Medical Staff and Clients

FROM: Dr. Wesley Kim, MD
Medical Director, DLS and QMC West

Jason Pon MB(ASCP), CHS
Manager, DLS Molecular

Amy Woron, PhD, MPH
VP & Technical Director
Microbiology & Molecular


Dr. Ana Ortega-Lopez, MD
Medical Director QMC Punchbowl,
North Hawaii and Molokai

DATE: October 21, 2025

SUBJECT: Implementation of *Clostridioides difficile* PCR Testing at Queen's Manamana and Queen's West Oahu

Diagnostic Laboratory Systems, Inc. (DLS) is pleased to announce that effective November 3, 2025 *C. difficile* PCR testing will be performed at the Queen's Manamana and Queen's West Oahu labs. Decentralization of the Cepheid Xpert® *C. diff*/Epi assay will shorten turnaround times, especially on nights and weekends. There is no change to order codes or reflex criteria; PCR for the toxin gene will continue to be performed automatically after a GDH -/Toxin+ or GDH+/Toxin- combination.

This assay will also detect *C. difficile* 027/NAP1/BI, a hypervirulent strain that produces binary toxin and exhibits high resistance to fluoroquinolones. This target is intended for epidemiologic surveillance only and will not appear on patient reports; results will be made available to Infection Prevention and Control upon request.



As a reminder, formed stool specimens are unacceptable for *C. difficile* testing and will be rejected. Laboratory results should be interpreted in conjunction with clinical presentation and an ID consultation may be warranted.

Please refer any questions to Margo David, Manager - Manamana 808-356-7725, Lina Bergman, Manager – West Oahu 808-485-6610 or Client Services at 808-589-5101.